title: [Guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management].
abstract: OBJECTIVE
  Provide guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic Overactive Bladder management.
  
  
  METHODS
  Guidelines using formalized consensus guidelines method. These guidelines have been validated by a group of 13 experts quoting proposals, subsequently reviewed by an independent group of experts.
  
  
  RESULTS
  In the case of patients with urinary tract infection, it must be treated and injection postponed. Before proposing an injection, it is recommended to ensure the feasibility and acceptability of self-catheterisation by patient. The injection can be performed after local anesthesia of the bladder and urethra (lidocaine), supplemented where necessary by nitrous oxide inhalation and sometimes under general anesthesia. Injection is performed in the operating room or endoscopy suite. The bladder should not be too filled (increased risk of perforation). Treatment should be applied in 10 to 20 injections of 0.5 to 1mL homogeneously distributed in the bladder at a distance from the urethral orifices. It is not recommended to leave a urinary catheter in place except in cases of severe hematuria. The patient should be monitored until resumption of micturition. After the first injection, an appointment must be scheduled within 3 months (micturition diary, uroflowmetry, measurement of residual urine and urine culture). Performance of self-catheterisation should be questioned in the case of a symptomatic post-void residual and/or a residue>200mL. A new injection may be considered when the clinical benefit of the previous injection diminishes (between 6 and 9 months). A period of three months must elapse between each injection.
  
  
  CONCLUSIONS
  Implementation of these guidelines may promote best practice usage of BoNTA with optimal risk/benefit ratio.
authors.affiliation: Service d'urologie, hôpital Bichat, 46, rue Henri-Huchard, 75018 Paris, France. Electronic address: jean-francois.hermieu@bch.aphp.fr.
authors.forename: J-F
authors.initials: JF
authors.lastname: Hermieu
authors.forename: P
authors.initials: P
authors.lastname: Ballanger
authors.forename: G
authors.initials: G
authors.lastname: Amarenco
authors.forename: E
authors.initials: E
authors.lastname: Chartier-Kastler
authors.forename: M
authors.initials: M
authors.lastname: Cosson
authors.forename: P
authors.initials: P
authors.lastname: Costa
authors.forename: B
authors.initials: B
authors.lastname: Fatton
authors.forename: X
authors.initials: X
authors.lastname: Deffieux
authors.forename: P
authors.initials: P
authors.lastname: Denys
authors.forename: X
authors.initials: X
authors.lastname: Gamé
authors.forename: F
authors.initials: F
authors.lastname: Haab
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
authors.forename: L
authors.initials: L
authors.lastname: Le Normand
authors.forename: A
authors.initials: A
authors.lastname: Ruffion
authors.forename: C
authors.initials: C
authors.lastname: Saussine
mesh_terms: D000283:Administration, Intravesical; D000779:Anesthetics, Local / Q000008:administration & dosage; D019072:Antibiotic Prophylaxis; D000925:Anticoagulants / Q000009:adverse effects; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D000075202:Contraindications; D003558:Cystoscopy; D004334:Drug Administration Schedule; D005602:France; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects; D012648:Self Care; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014546:Urinary Catheterization; D014552:Urinary Tract Infections / Q000150:complications / Q000517:prevention & control
chemical_list: D000779:Anesthetics, Local; D000925:Anticoagulants; D009465:Neuromuscular Agents; D010975:Platelet Aggregation Inhibitors; D008012:Lidocaine; D019274:Botulinum Toxins, Type A
keywords: Botox(®); Botulinum toxin; Hyperactivité vésicale idiopathique réfractaire; Refractory idiopathic overactive bladder; Toxine botulinique; Urodynamic; Urodynamique